SG10202100921YA - Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy - Google Patents

Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Info

Publication number
SG10202100921YA
SG10202100921YA SG10202100921YA SG10202100921YA SG10202100921YA SG 10202100921Y A SG10202100921Y A SG 10202100921YA SG 10202100921Y A SG10202100921Y A SG 10202100921YA SG 10202100921Y A SG10202100921Y A SG 10202100921YA SG 10202100921Y A SG10202100921Y A SG 10202100921YA
Authority
SG
Singapore
Prior art keywords
cadherin
extracellular domain
cancer therapy
related methods
soluble extracellular
Prior art date
Application number
SG10202100921YA
Inventor
Sabine Brouxhon
M Kerry O'banion
Stephanos Kyrkanides
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of SG10202100921YA publication Critical patent/SG10202100921YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
SG10202100921YA 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy SG10202100921YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40736710P 2010-10-27 2010-10-27

Publications (1)

Publication Number Publication Date
SG10202100921YA true SG10202100921YA (en) 2021-03-30

Family

ID=45994754

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10202100921YA SG10202100921YA (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
SG2013032875A SG189547A1 (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
SG10201604467PA SG10201604467PA (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2013032875A SG189547A1 (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
SG10201604467PA SG10201604467PA (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Country Status (13)

Country Link
US (4) US20130287784A1 (en)
EP (1) EP2632489B1 (en)
JP (1) JP6243737B2 (en)
KR (1) KR20140075639A (en)
CN (1) CN103582494A (en)
AU (1) AU2011319777B2 (en)
BR (1) BR112013010535A2 (en)
CA (1) CA2816358A1 (en)
ES (1) ES2784385T3 (en)
MX (2) MX357167B (en)
RU (1) RU2013123792A (en)
SG (3) SG10202100921YA (en)
WO (1) WO2012058418A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
JP2015514062A (en) * 2012-03-15 2015-05-18 ザ リサーチ ファウンデーション フォー ザ ステイト ユニバーシティ オブ ニューヨーク Combination therapy comprising an inhibitor of the extracellular domain of E-cadherin
US9411750B2 (en) 2012-07-30 2016-08-09 International Business Machines Corporation Efficient calibration of a low power parallel data communications channel
US9474034B1 (en) 2015-11-30 2016-10-18 International Business Machines Corporation Power reduction in a parallel data communications interface using clock resynchronization
EP3427514B1 (en) 2016-03-10 2022-01-19 Cable Television Laboratories, Inc. Methods for latency reduction
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service
US10321351B2 (en) 2017-03-02 2019-06-11 Cable Television Laboratories, Inc. System and method for grant assignment
US10738127B2 (en) 2016-06-10 2020-08-11 Veritas Biotecnologia Ltda Monoclonal antibodies prevent cell surface protein shedding and block tumor growth
US10420085B2 (en) 2016-10-07 2019-09-17 Cable Television Laboratories, Inc. System and method for grant assignment
US10825479B2 (en) 2018-05-11 2020-11-03 Axon Enterprise, Inc. Systems and methods for cross-redaction

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR940009084B1 (en) 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 Antenna system for magnetic and resonant circuit detection
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
DE69229477T2 (en) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methods for the production of humanized antibodies
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6004554A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1994011401A1 (en) * 1992-11-17 1994-05-26 Yale University Human homolog of the e-cadherin gene and methods based thereon
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6723320B2 (en) * 1996-07-24 2004-04-20 Gsf Forschungszentrum Fur Umwelt Und Geshundheit Gmbh Mutations of E cadherin as a basis for the diagnosis and therapy of human malignant tumors
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
WO2002034880A2 (en) * 2000-10-23 2002-05-02 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
WO2002081655A2 (en) 2001-03-28 2002-10-17 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
AU2004206967B2 (en) 2003-01-23 2009-10-29 University Of Rochester Herpesvirus amplicon particles
CN102753579A (en) * 2009-05-01 2012-10-24 国立大学法人东京大学 Anti-cadherin antibody

Also Published As

Publication number Publication date
AU2011319777B2 (en) 2016-12-08
CN103582494A (en) 2014-02-12
MX357167B (en) 2018-06-28
SG10201604467PA (en) 2016-07-28
CA2816358A1 (en) 2012-05-03
WO2012058418A2 (en) 2012-05-03
US20160046701A1 (en) 2016-02-18
AU2011319777A1 (en) 2013-05-23
KR20140075639A (en) 2014-06-19
MX2018007983A (en) 2023-02-23
JP6243737B2 (en) 2017-12-06
EP2632489A2 (en) 2013-09-04
WO2012058418A3 (en) 2012-07-19
US20210380671A1 (en) 2021-12-09
BR112013010535A2 (en) 2017-11-07
EP2632489A4 (en) 2014-06-18
US20130287784A1 (en) 2013-10-31
RU2013123792A (en) 2014-12-10
EP2632489B1 (en) 2020-01-15
MX2013004790A (en) 2014-01-17
SG189547A1 (en) 2013-05-31
JP2014500862A (en) 2014-01-16
ES2784385T3 (en) 2020-09-24
US20190352380A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
SG10201604467PA (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
EP2640359A4 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
HK1213488A1 (en) Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
EP2904106A4 (en) Compositions and methods for targeting stromal cells for the treatment of cancer
HK1211832A1 (en) Novel compositions and uses of anti-hypertension agents for cancer therapy
ZA201300567B (en) Methods and compositions for liver cancer therapy
IL225471A0 (en) Compositions and methods for the prevention and treatment of cancer
DK2608777T3 (en) Compositions and Methods for Cardiac Therapy
HRP20180563T1 (en) Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
EP2688594A4 (en) Methods and compositions for the treatment of cancer
IL238177A0 (en) Methods and compositions for the treatment of cancer
EP2526118A4 (en) Compositions and methods for treatment of ovarian cancer
SG10201500124VA (en) Methods and Compositions for Treating Cancer
EP2558085A4 (en) Compositions and methods for the prevention and treatment of cancer
IL222739A0 (en) Methods of use soluble cd24 for therapy of rhematoid arthritis
IL226095A0 (en) Pyridine derivatives and their use pharmaceutical compositions for treating cancer
PL2605764T3 (en) Compositions for the treatment of cancer
IL226252B (en) Combination of fgfr1 extracellular domain and an additional agent for treatment of cancer
EP2911692A4 (en) Use of endocytosis inhibitors and antibodies for cancer therapy
EP2635273A4 (en) Isoflavonoid compositions and methods for the treatment of cancer
EP2646042A4 (en) Tumour cytotoxic agent and methods thereof
HUE037382T2 (en) Methods of treating cancer comprising targeting nqo1
WO2011130697A3 (en) Tissue targeting
EP2522366A4 (en) Targeting agent for tumor site
WO2012003421A9 (en) Combinational compositions and methods for treatment of cancer